Table 4.
Microbiology
| |
Azithromycin |
|
Placebo |
|
|---|---|---|---|---|
| Baseline | 12 weeks | baseline | 12 weeks | |
|
Microbiology, n (%) |
(n = 40) |
(n = 30) |
(n = 41) |
(n = 31) |
|
Streptococcus pneumoniae |
5 (11.9) |
0 (0) |
3 (7.1) |
2 (4.8) |
|
Haemophilus influenzae |
11 (27.5) |
4 (13.3)* |
7 (17.1) |
10 (32.3) |
|
Moraxella catarrhalis |
5 (12.5) |
0 (0) |
5 (12.2) |
3 (9.7) |
|
Pseudomonas aeruginosa |
0 (0) |
1 (3.3) |
2 (4.9) |
3 (9.7) |
| Staphylococcus aureus | 1 (2.5) | 0 (0) | 1 (2.4)* | 0 (0) |
*one patient with azithromycin resistant bacteria.